ArticleMolecular biology reports2026
Integrative analysis identifies candidate biomarkers for bladder cancer: evidence from genomic and clinical validation.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundBladder cancer (BCa) is a highly prevalent urological malignancy and one of the most frequently occurring cancers worldwide, necessitating the development of diagnostic and therapeutic biomarkers. This study aimed to explore candidate genes that may be involved in the carcinogenesis of BCa. MATERIALS AND
methodsBCa gene expression data from the Gene Expression Omnibus (GEO) database were analyzed. Both differential expression analysis and weighted gene co-expression network analysis (WGCNA) were performed on datasets (GSE236932, GSE133624) to identify the key modules and hub genes. We subsequently extracted genes from the top modules positively correlated with tumor traits identified via WGCNA and intersected them with differentially expressed genes (DEGs) in each dataset. Finally, the overlapping genes were screened for their therapeutic potential as biomarkers in bladder cancer, and quantitative Real-Time PCR (qRT-PCR) was executed to validate the expression patterns of the most promising candidate genes in clinical tissue samples.
resultsIntegrative analysis revealed a set of hub genes potentially involved in bladder cancer, including PSMG3, ESRP1, GRHL2, MAL2, CDH1, AP1M2, PAFAH1B3, PRKCZ, MAPK13, and RAB25. Among these, PAFAH1B3 and PSMG3 emerged as notable novel candidates. qRT-PCR validation further underscored the significant overexpression of these genes in BCa samples, with approximately two-fold changes relative to normal tissues.
conclusionsThis study suggests that PAFAH1B3 and PSMG3 may serve as valuable biomarkers and potential therapeutic targets in bladder cancer. However, further investigations are needed to establish their biological function and clinical relevance.
Indexed as
Identifiers
42470583What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.